Anti-Hypertensive Drugs - Malta

Malta

Highlights

In Malta, the revenue in the Anti-Hypertensive Drugs market is estimated to reach US$3.22m by 2024.
It is expected to exhibit an annual growth rate (CAGR 2024-2029) of 0.71%, leading to a market volume of US$3.34m by 2029.
When compared globally, United States is projected to generate the highest revenue of US$12.29bn in 2024.
Malta's pharmaceutical market is experiencing a rising demand for anti-hypertensive drugs due to the country's high prevalence of hypertension.

Key regions:

Market definitionIn-Scope/Out-of-scopeMarket structureReportsMethodology

The Anti-Hypertensive Drugs market in Malta has been showing steady growth in recent years.

Customer preferences: Malta has an aging population, which is a key driver of the demand for anti-hypertensive drugs. Additionally, a growing awareness of the importance of managing hypertension has led to an increase in the number of patients seeking treatment.

Trends in the market: The market for anti-hypertensive drugs in Malta is dominated by a few key players, with generic drugs being the most commonly prescribed. However, there has been a shift towards newer, more expensive drugs in recent years, particularly among younger patients. This trend is likely to continue as the Maltese healthcare system continues to invest in new treatments.

Local special circumstances: One factor that has contributed to the growth of the anti-hypertensive drugs market in Malta is the country's high prevalence of hypertension. This is partly due to the Maltese diet, which is high in salt and processed foods. Additionally, the country's hot climate may also contribute to higher rates of hypertension.

Underlying macroeconomic factors: Malta has a strong economy with a high level of government spending on healthcare. This has allowed for the development of a well-funded and well-equipped healthcare system, which is able to provide high-quality care to patients. Additionally, Malta's membership in the European Union has facilitated the importation of drugs from other EU countries, which has helped to keep prices low.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.